Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Europe’s VC Retreat May Threaten Drug Innovation There

This article was originally published in The Pink Sheet Daily

Executive Summary

The number of VC firms actively investing in European biotech and life science companies - and the funds available for investing - could fall below the critical mass considered vital for supporting innovation, investors warn.

You may also be interested in...



With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders

The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.

France's Adocia Completes 2012's First Euro Biotech IPO

French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes

Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel